Clinical Trials Sponsored by PX Biosolutions

Total 109 results

PX Biosolutions

Completed

Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity

Cervical Cancer | Acute Myeloid Leukemia | Chronic Myeloid Leukemia | Ovarian Serous Adenocarcinoma | Undifferentiated Carcinoma of Ovary | Cervical Intraepithelial Neoplasia, Grade 3

Australia
Emergent BioSolutions

Terminated

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

T-cell Lymphoma
Emergent BioSolutions

Terminated

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Healthy Volunteers

United States
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
Emergent BioSolutions

Completed

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001)

Smallpox

United States
Prothya Biosolutions

Completed

Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy

Myocardial Diseases | Parvovirus B19, Human

Netherlands
Prothya Biosolutions

Completed

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Angioedema

Netherlands
Prothya Biosolutions

Completed

Kinetics, Efficacy and Safety of C1-Esteraseremmer-N

Hereditary Angioedema Type I | Angioneurotic Edema

Netherlands
Prothya Biosolutions

Completed

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Hemophilia B

Netherlands
Prothya Biosolutions

Completed

Efficacy and Safety of IVIG-L in ITP Patients

Purpura, Thrombocytopenic, Idiopathic

Poland
Emergent BioSolutions

Completed

Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)

Smallpox

United States
Emergent BioSolutions

Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Smallpox

United States
Emergent BioSolutions

Completed

VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV

Smallpox Vaccine Adverse Reaction

Canada
Emergent BioSolutions

Completed

Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

Opioid Overdose

United States
Emergent BioSolutions

Completed

Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)

Zika Virus Infection | Zika Virus Disease

Canada
Emergent BioSolutions

Completed

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

T Cell Lymphoma
Emergent BioSolutions

Enrolling by invitation

BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients

Botulism
Prothya Biosolutions

Completed

Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery

CPB | Oral Anticoagulant Therapy

Belgium
Prothya Biosolutions

Completed

Pharmacokinetics of New HepBQuin

Healthy

Germany
Prothya Biosolutions

Completed

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml (Nanogam)

Primary Immunodeficiency

Netherlands
Prothya Biosolutions

Completed

Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response (Subklasse)

Infections | IgG Deficiency

Netherlands
Prothya Biosolutions

Completed

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Angioedema

Netherlands
Prothya Biosolutions

Completed

Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients

Hypogammaglobulinemia

Netherlands
Emergent BioSolutions

Completed

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

Typhoid

United States
Prothya Biosolutions

Active, not recruiting

Apotransferrin in Atransferrinemia

Congenital Atransferrinemia

Spain, Germany, Italy
Emergent BioSolutions

Completed

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Influenza A H3N2 | Influenza A H1N1

United States, Spain, Canada, Puerto Rico
Emergent BioSolutions

Completed

Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel

Smallpox

United States
Emergent BioSolutions

Completed

ACAM2000® Myopericarditis Registry

Myocarditis | Pericarditis

United States
Emergent BioSolutions

Completed

Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
Emergent BioSolutions

Completed

A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

Anthrax Infection

United States
Emergent BioSolutions

Completed

Safety Surveillance Study of ACAM2000® Vaccinia Vaccine

Smallpox

United States
Emergent BioSolutions

Completed

Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)

Human Influenza

Australia
Prothya Biosolutions

Terminated

Apotransferrin in Patients With β-thalassemia

β-thalassemia Intermedia

Netherlands
Immune Biosolutions Inc

Completed

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

COVID-19

South Africa, Brazil
Ampel BioSolutions, LLC

Completed

A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE (RIFLE)

Fatigue | Lupus Erythematosus, Systemic | Lupus Erythematosus

United States
Ampel BioSolutions, LLC

Recruiting

Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE) (ReLATE)

Lupus Erythematosus, Systemic

United States
Emergent BioSolutions
GlaxoSmithKline

Completed

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

Infections, Bacterial

United States
Immune Biosolutions Inc

Completed

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

COVID-19

South Africa, Ukraine
Immune Biosolutions Inc

Completed

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

COVID-19

Ukraine, South Africa
Pantec Biosolutions AG

Unknown

Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis

Psoriatic Plaque

Switzerland
Bavarian Nordic
Emergent BioSolutions

Completed

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Typhoid Fever

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine (CHIKV VLP)

Chikungunya Virus

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

Cholera

United States
Bavarian Nordic
Emergent BioSolutions

Completed

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

Cholera (Disorder)

United States
Bavarian Nordic
Emergent BioSolutions

Completed

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Cholera

United States
Axio Biosolutions Pvt. Ltd.

Completed

Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure (AHD)

Percutaneous Coronary Intervention | Angioplasty | Angiography

India
Axio Biosolutions Pvt. Ltd.

Completed

Studying Safety & Efficacy of Axiostat® Dressing in Acute Hemorrhage Due to Trauma-Comparative Study

Bleeding

India
Biosolution Co., Ltd.

Recruiting

Phase 2 Clinical Trial of CartiLife® in the United States

Articular Cartilage Defect | Articular Cartilage Degeneration

United States
Axio Biosolutions Pvt. Ltd.

Recruiting

To Evaluate the Efficacy and Safety of MaxioCel Versus Aquacel Extra for the Management of Chronic Wounds

Wound

India
Bavarian Nordic
Emergent BioSolutions

Completed

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317

Chikungunya Virus

United States

3

Subscribe